Therapeutic Response

PD-L1 >= 50%, Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Cemiplimab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Libtayo (cemiplimab) [product monograph]. HC. Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.